Research programme: antibacterials - Polyphor

Drug Profile

Research programme: antibacterials - Polyphor

Alternative Names: POL6137; POL7001

Latest Information Update: 23 Feb 2010

Price : $50

At a glance

  • Originator Polyphor
  • Class
  • Mechanism of Action Antimicrobial cationic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 20 Feb 2010 Preclinical development is ongoing Switzerland
  • 28 Oct 2008 Antimicrobial and pharmacokinetcis data from preclinical studies in P. aeruginosa infections presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008) ,,
  • 17 Apr 2008 Preclinical trials in Gram-negative infections in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top